Table 1.

Demographic Characteristics of Study Population*

Conventional (n = 13)rhG-CSF 5
μg (n = 5)
rhG-CSF 10 μg (n = 10)
Birth weight (g)
 Mean732 ± 85824 ± 104802 ± 56
 Range356–1100579–1210536–1130
 Median670805780
Gestational age (wk)
 Mean28 ± 128 ± 127 ± 1
 Range26–3225–3124–30
 Median272828
Sex (M/F)8/54/18/2
Growth retardation32 5  (38%)3  (60%)8  (80%)
Cesarean delivery9  (69%)4  (80%)9  (90%)
5-min Apgar <31  (8%)0  (0%)0  (0%)
Respiratory distress syndrome13  (100%)5  (100%)10  (100%)
Surfactant use11  (85%)4  (80%)8  (80%)
Umbilical arterial catheter11  (85%)4  (80%)8  (80%)
Umbilical venous catheter8  (61%)4  (80%)6  (60%)
Percutaneous intravenous central venous catheter12  (92%)3  (60%)9  (90%)
Number infected702
Absolute neutrophil count at onset of infection
  Mean8048 ± 3048NA21980 ± 3582
  Range1104–19564NA8316–34580
  Median11274NANA
Age at rhG-CSF treatment (d)
  MeanNA4.2 ± 0.134.4 ± 0.24
  RangeNA4–54–5
  MedianNA44
Age at diagnosis of sepsis (d)
  Mean15 ± 5NA17 ± 4
  Range5–27NA13–21
  Median14NANA
  • Abbreviations: rhG-CSF, recombinant human granulocyte colony-stimulating factor; NA, not applicable.

  • * Note: Numbers represent the number of patients with each item unless otherwise indicated. Growth retardation = <10 percentile for weight.32